

Sold

14.4%


Expenses -29.1%

PHARMACEUTICAL 2020

Revance Therapeutics Inc. Rank 181 of 362

Selling, Cost of Goods General and Research and Other Expenses Administrative Development 31.6% Expense -58.9% -16.1% 14.4% 31.6% -16.1% -58.9% Other Net Property and Assets, Intangible Revenues Other Assets Equipment 2.98% Income Current Assets -64.1% 3.24% 146% -20.0% 10.6% -29.1% 10.6% -64.1% 3.24% 2.98% 146% -20.0% Liabilities, Net Income

REVANCE







PHARMACEUTICAL 2020

Revance Therapeutics Inc. Rank 181 of 362

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 146% points. The greatest weakness of Revance Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is -175%, being 127% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	296,602
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	40,979
Liabilities, Non-Current	73,818
Other Assets	28,930
Other Compr. Net Income	11
Other Expenses	0
Other Liabilities	0
Other Net Income	5,030
Property and Equipment	14,755
Research and Development	102,861
Revenues	413
Selling, General and Administrative Expense	62,011

Output Variable	Value in 1000 USD
Assets	340,287
Liabilities	114,797
Expenses	164,872
Stockholders Equity	225,490
Net Income	-159,429
Comprehensive Net Income	-159,424
Economic Capital Ratio	-175%

